ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1348	National Cancer Institute	Html	en	Childhood Brain and Spinal Cord Tumors Treatment Overview (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of various childhood brain tumors.	extent 0.337038 subsequent treatment 0.517666 Secondary tumors 0.579906 clinical parameters 0.491035 tumor recurrence. 0.623825 survival rates 0.51115 Long-term management 0.517392 chemotherapy 0.381898 cancer therapy 0.545899 complete evaluation 0.500262 malignant tumors 0.805007 malignant lesions. 0.574087 surgical re-resection 0.493219 need 0.367173 adolescents 0.338935 treatment-related brain necrosis 0.687273 diagnosis 0.335644 long-term survivors. 0.521208 secondary tumor 0.621568 delay 0.350588 radiation therapy 0.839862 reappearance 0.354633 Long-term sequelae 0.545468 late effects 0.655763	initial presence 0.550902 childhood cancer mortality 0.80921 CNS 0.340422 surgical intervention 0.48867 Systemic relapse 0.562929 Refer 0.342732 multidisciplinary approach 0.498495 specific information 0.517079 lower-grade lesions 0.50599 preliminary results 0.50527 molecular makeup. 0.495814 initial tumor type 0.822989 initial treatment 0.69405 primary tumor site 0.789307 close monitoring 0.52126 tumor transformation 0.62382 younger children 0.509243 adolescent cancer survivors 0.999281 childhood brain tumors 0.792254 Dramatic improvements 0.534814 PDQ summary 0.529827 Biopsy 0.34098 neurologic development 0.517779 time 0.38324	CLICK HERE
1402	National Cancer Institute	Html	en	Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.	T-cell lymphoblastic lymphoma 0.616756 mediastinal B-cell lymphoma 0.654258 Pediatric Non-Hodgkin Lymphoma 0.567507 mature B-cell 0.675642 Engl J Med 0.525188 B-cell non-Hodgkin lymphoma 0.746462 children 0.65412 mature B-cell leukemia 0.544897 cell lymphoma outcome 0.543686 lymphoblastic lymphoma stage 0.540387 pediatric-type follicular lymphoma 0.574777 large B-cell lymphomas 0.528398 large cell lymphoma 0.779097 pediatric anaplastic lymphoma 0.540067 adolescents 0.539146 Burkitt lymphoma 0.638477 mediastinal large B-cell 0.573557 childhood B-cell non-Hodgkin 0.52722 diffuse large b-cell 0.665879 anaplastic large-cell lymphoma 0.616485 center-derived B-cell lymphoma 0.609426 Burkitt lymphoma incidence 0.577758 cell lymphoma cases 0.534062 Leuk Lymphoma 0.529329 large B-cell lymphoma 0.815777	cell lymphoma patients 0.528087 mature B-cell lymphoma 0.609056 et al. 0.801373 Br J Haematol 0.629196 Cairo MS 0.571856 primary mediastinal B-cell 0.5557 Pediatr Blood Cancer 0.817055 childhood B-cell 0.532059 diffuse large-B-cell lymphoma 0.523303 Secondary non-Hodgkin lymphoma 0.572995 mature B-cell non-Hodgkin 0.643468 lymphoblastic lymphoma 0.618923 Abstract 0.750082 cancer group 0.553869 lymphoma 0.902345 Clin Oncol 0.644225 childhood non-Hodgkin lymphoma 0.549011 high-stage Burkitt lymphoma 0.543865 B-cell lymphoma subgroups 0.565819 non-hodgkin lymphoma 0.766463 recurrent non-Hodgkin lymphoma 0.543912 anaplastic large cell 0.660109 oncology group 0.53775 Burkitt-like lymphoma 0.528197	CLICK HERE
1451	National Cancer Institute	Html	null	Unusual Cancers of Childhood Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of unusual cancers of childhood such as cancers of the head and neck, chest, abdomen, reproductive system, skin, and others.			CLICK HERE
1468	National Cancer Institute	Html	null	Testicular Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of testicular cancer.			CLICK HERE
1498	National Cancer Institute	Html	en	Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of lip and oral cavity cancer.	retromolar trigone 0.457467 lesions 0.51335 cone radiation therapy 0.449302 stage IV tumors 0.388096 station nodes 0.404586 radiation therapy. 0.414397 lip 0.39553 larger lesions 0.408688 oral cavity cancer 0.391261 upper gingiva 0.475854 local recurrence 0.42994 early lesions 0.429301 World Health Organization 0.457603 patients 0.399778 early cancers 0.501066 small cancers 0.408462 interstitial radiation sources 0.430653 advanced cancers 0.459827 neck cancers 0.384982 lymph nodes 0.55579 radiation therapy 0.932988 cancers 0.524279 lymph node drainage 0.410464 anterior tongue 0.427579 treatment 0.469588	radiation modifiers 0.407878 lichen planus 0.388656 radiation oncologists 0.396567 posterior cervical nodes 0.416429 oral cavity tumors 0.396446 cervical lymph nodes 0.491468 distant metastases 0.456495 regional lymph node 0.41022 Precancerous lesions 0.394835 buccal mucosa 0.38527 radical radiation therapy 0.447851 moderately advanced lesions 0.488166 external-beam radiation therapy 0.451492 oral cavity cancers 0.431571 cosmetic results 0.421228 radiation treatment 0.406818 stage 0.394996 hard palate 0.551429 local control rates 0.433778 oral cavity 0.569458 regional lymph nodes 0.478345 radiation oncologist 0.475855 Small superficial cancers 0.415309 squamous cell carcinoma 0.47595	CLICK HERE
1721	National Cancer Institute	Html	en	Cruciferous Vegetables and Cancer Prevention	A fact sheet that summarizes the results of studies about cruciferous vegetables and cancer. Includes a list of cruciferous vegetables and dietary recommendations.	Netherlands—the Netherlands Cohort 0.505069 vegetable consumption 0.464589 cruciferous vegetables 0.977553 additional cohort study 0.516082 lung cancer 0.572949 anticancer effects 0.474858 colorectal cancer risk 0.625293 U.S. analysis—using data 0.461382 Breast Cancer Detection 0.503706 case-control studies 0.513186 prostate cancer risk 0.623248 lower risk 0.488713 glutathione S-transferase M1 0.504449 American Journal 0.4921 cruciferous vegetable intakes 0.595836 dark-green vegetables 0.522884 cancer chemopreventive actions 0.501377 cruciferous vegetable intake 0.689816 Cancer Epidemiology 0.57031 cohort studies 0.539353 glutathione S-transferase polymorphisms 0.4667 European Prospective Investigation 0.461912 cohort study 0.686602 cancer prevention 0.479265 United States 0.545427	Different vegetables 0.524746 multiethnic case-control study 0.487149 National Cancer Institute 0.594926 Project follow-up cohort 0.488384 Multiethnic Cohort Study 0.506189 good fiber source 0.467963 cancer researchers 0.489622 prospective cohort study 0.510047 breast cancer risk 0.615894 fruit consumption 0.483024 Clinical Nutrition 0.460261 breast cancer 0.641649 colon cancer risk 0.523965 biologically active compounds 0.464394 Goldbohm RA 0.48606 lung cancer risk 0.545247 C. Brassica vegetables 0.534883 prospective study 0.585742 glutathione S-transferase 0.517935 lung cancer mortality 0.501562 et al 0.817121 cancer risk 0.800364 Netherlands Cohort Study 0.590813 lower lung cancer 0.502455	CLICK HERE
1771	National Cancer Institute	Html	es	Sofocos y sudores nocturnos (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las causas y el tratamiento de los sofocos y sudores nocturnos en los pacientes de cáncer.	cancer treatment 0.37896 Treatment Group Trial 0.316121 ncctg trial 0.313822 Treatment Group hot 0.319139 menopausal hot 0.328045 Loprinzi CL 0.615617 trial with 0.311 menopausal symptoms 0.33934 Sin embargo 0.333136 Barton DL 0.356229 with early stage 0.313223 black cohosh 0.329892 Sloan JA 0.313934 ameliorating tamoxifen-induced hot 0.310913 randomized trial 0.317475 with hot 0.314342 phase iii 0.323066 active nonhormonal hot 0.311258 symptoms after breast 0.31045 Natl Cancer Inst 0.330125 during menopausal hot 0.313013 North Central Cancer 0.333247 tamoxifen-induced hot 0.32746 Women's Health Initiative 0.336331 Cancer Ther 0.316362	breast carcinoma 0.310376 Support Oncol 0.317335 randomized controlled 0.353057 Initiative Randomized Trial 0.310959 Cognitive behavioural treatment 0.310884 hot flash studies 0.31899 Hot Flash Related 0.322478 experiencing tamoxifen-induced hot 0.310785 problematic menopausal hot 0.31265 hierba sonajero 0.329084 estrogen replacement therapy 0.321006 Support Care Cancer 0.31053 Cancer Res Treat 0.338604 Cancer Treatment Group 0.35326 after breast 0.314947 Clin Oncol 0.532082 breast cancer 0.920092 health initiative randomized 0.310524 hot flash 0.362781 Pilot evaluation 0.324608 early stage breast 0.318416 Central Cancer Treatment 0.352938 learned from hot 0.311156 Stearns V 0.318536	CLICK HERE
1830	National Cancer Institute	Html	es	Tratamiento de la leucemia mielógena crónica (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia mielógena crónica.	imatinib treatment 0.309815 associated with 0.307718 Saglio G 0.311488 Imatinib plus 0.308886 mayoría imatinib 0.309903 with chronic myeloid 0.371977 Sin embargo 0.315782 Kantarjian HM 0.372759 standard-dose imatinib therapy 0.309084 myeloid leukemia patients 0.32923 Cortes JE 0.313764 chronic myeloid leukemia 0.996248 or imatinib 0.327327 myelogenous leukemia patients 0.309285 Philadelphia chromosome-positive 0.307544 TCM alogénico 0.343658 chronic myelomonocytic leukemia 0.306491 patients with chronic 0.376511 Rosti G 0.305694 leucemia mielógena 0.3214 stem cell transplantation 0.309631 chronic myelogenous leukemia 0.537094 with imatinib 0.31893 Guilhot F 0.305867 vs imatinib 0.308365	Chronic Leukemia 0.308312 Versus Imatinib Study 0.318542 patients with philadelphia 0.308802 dasatinib or imatinib 0.311418 versus imatinib 0.331295 Jabbour E 0.308732 patients with 0.421072 myeloid leukemia treated 0.313347 Treatment-Naïve Chronic Myeloid 0.309823 marrow transplantation 0.313614 leukemia treated with 0.314928 Dasatinib Versus Imatinib 0.321251 bone marrow transplantation 0.310388 Leukemia Patients Trial 0.308496 newly diagnosed chronic 0.341689 treated with imatinib 0.310526 imatinib depends 0.308315 imatinib versus 0.310194 chronic granulocytic leukemia 0.306345 tirosina cinasa 0.443764 Clin Oncol 0.407181 bone marrow 0.312247 myelogenous leukemia with 0.307043 treated with 0.317153	CLICK HERE
3578	National Cancer Institute	Html	en	Research Areas	Making sustained progress against cancer requires advances across the research continuum. Learn about the breadth of NCI's work and the programs the institute supports to advance cancer research.	National Cancer Institute 0.966549		CLICK HERE
3579	National Cancer Institute	Html	en	Cancer Health Disparities Research	NCI is addressing cancer health disparities through its efforts in basic research, community-level programs, and more.	cancer treatment 0.363689 cancer control continuum—from 0.369693 health care disparities 0.45285 American Cancer Society 0.373854 Breast Cancer Genetic 0.374611 NCI research programs 0.364956 cancer health disparities—such 0.406746 colorectal cancer 0.373832 American Breast Cancer 0.39202 Colorectal Cancer Outreach 0.36747 public health officials 0.365199 breast cancer outcome 0.373209 clinical cancer research 0.388692 Reduce Cancer Health 0.386549 health care facilities 0.400047 Breast Cancer Consortium 0.371087 population groups 0.362749 African American Breast 0.367467 care delivery research 0.356797 public health communities 0.394704 cancer health disparities 0.942995 NCI-Designated Cancer Centers. 0.367758 Documented cancer health 0.404937 certain racial/ethnic populations 0.356837 cancer research community 0.391405	Cancer Health Equity 0.385722 cancer research continuum 0.381244 cancer prevention 0.353808 prostate cancer deaths 0.379501 health disparities research 0.467802 cancer research 0.471213 African American men 0.354676 cancer screenings 0.355012 cancer screening rates 0.368257 cancer care—from access 0.379244 Breast Cancer Epidemiology 0.371467 African American women 0.401312 complex health care 0.371446 advanced cancer diagnoses—in 0.382581 community health educators 0.353702 breast cancer 0.431984 cancer care delivery 0.39176 cancer disparities 0.490093 NCORP cancer care 0.377954 experience cancer-related health 0.363186 cancer clinical trials 0.389742 cancer risk 0.352747 cancer death rates 0.384903 cancer incidence 0.357189	CLICK HERE